Investment Rating - The report does not specify a clear investment rating for the company [1]. Core Insights - The company reported a net loss of 750 million yuan in 2023, a decrease from 890 million yuan in 2022 [2]. - The core product, CT053, has been approved for market launch, targeting adult patients with relapsed or refractory multiple myeloma [2]. - The company is expanding its global production capacity, establishing vertical integration in three key stages of CAR-T manufacturing [3]. - Revenue forecasts for 2024-2026 are projected at 100 million yuan, 300 million yuan, and 700 million yuan respectively [4][10]. Financial Summary - For 2023, the company had cash and cash equivalents of 1.85 billion yuan [2]. - The expected revenue growth rates for 2024, 2025, and 2026 are 200% and 133.33% respectively [4]. - The net profit attributable to the parent company is projected to improve from -747.79 million yuan in 2023 to -215.37 million yuan in 2026 [4]. - Earnings per share (EPS) is expected to improve from -1.30 yuan in 2023 to -0.37 yuan in 2026 [4].
2023年年报点评：赛恺泽上市，期待2024年商业化